Skip to main content

Octagon Capital Advisors LP

13F filer · CIK 0001839435
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$1.11BU.S. long equity reported on 13F
Positions264 new · 7 closed
Net flow last quarter-$40.1MBuys minus sells
Top 10 positions weight78.5%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202626 positions
DNTHDianthus Therapeutics, Inc.$180M16.14%3.36%-5.4%Q3 2023
DFTXDefinium Therapeutics, Inc.$139M12.47%2.20%+20.9%Q1 2026
ABVXAbivax S.A.$132M11.89%1.26%+46.7%Q1 2025
COGTCogent Biosciences, Inc.$90.9M8.17%1.37%Not reportedQ3 2024
ALMSAlumis Inc.$79.7M7.16%Not reportedNot reportedQ4 2025
AVBPArriVent BioPharma, Inc.$68.5M6.15%4.08%Not reportedQ1 2024
TSHATaysha Gene Therapies, Inc.$66M5.93%2.98%+9.4%Q4 2020
BIOABioAge Labs, Inc.$42.8M3.85%3.82%Not reportedQ4 2025
MIRMMirum Pharmaceuticals, Inc.$39.7M3.57%0.52%Not reportedQ3 2022
KYMRKymera Therapeutics, Inc.$35.5M3.20%0.37%-27.1%Q2 2021
AKTSAktis Oncology, Inc.$31M2.78%1.80%Not reportedQ1 2026
XENEXenon Pharmaceuticals Inc.$29.6M2.66%0.51%Not reportedQ1 2026
PALIPalisade Bio, Inc.$21.5M1.93%5.92%Not reportedQ4 2025
OCULOcular Therapeutix, Inc$20.4M1.83%0.94%-34.5%Q1 2024
IRONDisc Medicine, Inc.$19.7M1.78%0.70%Not reportedQ2 2023
SMMTSummit Therapeutics Inc.$18.2M1.64%0.16%NewQ2 2026
PHVSPharvaris N.V.$15.8M1.42%0.70%+176.8%Q3 2024
ANLAdlai Nortye Ltd.$10.7M0.97%Not reportedNewQ2 2026
DTILPrecision Biosciences Inc$10.6M0.95%5.11%-39.6%Q4 2025
DBVTDBV Technologies S.A.$9.42M0.85%0.19%Not reportedQ2 2025
FTHFaeth Therapeutics, Inc.$9.03M0.81%1.40%NewQ2 2026
GYREGyre Therapeutics, Inc.$6.29M0.57%0.90%NewQ2 2026
TRVITrevi Therapeutics, Inc.$5.87M0.53%0.22%-78.8%Q1 2025
UNCYUnicycive Therapeutics, Inc.$4.69M0.42%3.59%Not reportedQ3 2024
CNTXContext Therapeutics Inc.$1.69M0.15%3.32%-41.9%Q1 2026
GOSSGossamer Bio, Inc.$1.28M0.11%1.59%Not reportedQ4 2020
Q1 2026Reported May 15, 202629 positions
DNTHDianthus Therapeutics, Inc.$163M18.08%3.57%-19.5%Q3 2023
COGTCogent Biosciences, Inc.$90.5M10.01%1.38%Not reportedQ3 2024
ABVXAbivax S.A.$75.4M8.34%0.86%-10.5%Q1 2025
ALMSAlumis Inc.$62.4M6.90%Not reported+11.9%Q4 2025
DFTXDefinium Therapeutics, Inc.$46.1M5.10%2.35%NewQ1 2026
AVBPArriVent BioPharma, Inc.$45.5M5.03%4.35%Not reportedQ1 2024
TSHATaysha Gene Therapies, Inc.$39.6M4.38%3.08%Not reportedQ4 2020
KYMRKymera Therapeutics, Inc.$35.4M3.92%0.52%-20.6%Q2 2021
MIRMMirum Pharmaceuticals, Inc.$31.3M3.46%0.56%Not reportedQ3 2022
BIOABioAge Labs, Inc.$30.6M3.38%3.94%+9.4%Q4 2025
CNTACentessa Pharmaceuticals PLC$29.8M3.30%0.48%Not reportedQ1 2023
KALVKalVista Pharmaceuticals, Inc.$29.2M3.23%2.83%+13.9%Q4 2024
XENEXenon Pharmaceuticals Inc.$28.5M3.15%0.51%NewQ1 2026
TERNTerns Pharmaceuticals, Inc.$27.9M3.09%0.46%Not reportedQ1 2024
OCULOcular Therapeutix, Inc$26.8M2.97%1.45%+20.7%Q1 2024
PALIPalisade Bio, Inc.$18M1.99%6.14%+7.4%Q4 2025
TRVITrevi Therapeutics, Inc.$17.7M1.96%1.16%-47.3%Q1 2025
IRONDisc Medicine, Inc.$17.3M1.91%0.71%Not reportedQ2 2023
AKTSAktis Oncology, Inc.$17.2M1.90%1.80%NewQ1 2026
CNTXContext Therapeutics Inc.$13.8M1.52%5.71%NewQ1 2026
DTILPrecision Biosciences Inc$12.3M1.36%8.67%+16.6%Q4 2025
DBVTDBV Technologies S.A.$12M1.33%0.19%Not reportedQ2 2025
UNCYUnicycive Therapeutics, Inc.$6.58M0.73%3.96%Not reportedQ3 2024
BBOTBridgeBio Oncology Therapeutics, Inc.$6.44M0.71%0.90%-31.1%Q1 2024
LXEOLexeo Therapeutics, Inc.$6.31M0.70%1.48%-36.2%Q4 2025
PHVSPharvaris N.V.$4.66M0.52%0.25%-75.4%Q3 2024
CATXPerspective Therapeutics, Inc.$3.3M0.37%0.69%Not reportedQ1 2024
EVMNEvommune, Inc.$3.3M0.37%0.40%-71.3%Q4 2025
GOSSGossamer Bio, Inc.$2.55M0.28%3.30%-44.3%Q4 2020
Q4 2025Reported Feb 17, 202626 positions
ABVXAbivax S.A.$102M12.38%0.96%-42.9%Q1 2025
DNTHDianthus Therapeutics, Inc.$99.6M12.09%5.59%Not reportedQ3 2023
COGTCogent Biosciences, Inc.$83.5M10.13%1.46%-18.2%Q3 2024
TSHATaysha Gene Therapies, Inc.$48.7M5.92%3.11%-2.3%Q4 2020
GOSSGossamer Bio, Inc.$43.1M5.24%5.96%-18.4%Q4 2020
KYMRKymera Therapeutics, Inc.$41.6M5.05%0.66%+48.6%Q2 2021
AVBPArriVent BioPharma, Inc.$39.7M4.81%4.64%Not reportedQ1 2024
TRVITrevi Therapeutics, Inc.$35.2M4.28%2.19%Not reportedQ1 2025
OCULOcular Therapeutix, Inc$31.9M3.87%1.22%0.0%Q1 2024
MNMDDefinium Therapeutics, Inc.$29.9M3.63%Not reported+4.7%Q1 2024
ALMSAlumis Inc.$24.7M3.00%Not reportedNewQ4 2025
PALIPalisade Bio, Inc.$22.5M2.73%6.00%NewQ4 2025
CDTXCidara Therapeutics, Inc.$22.1M2.68%0.32%Not reportedQ3 2025
BIOABioAge Labs, Inc.$21.1M2.57%4.27%NewQ4 2025
KALVKalVista Pharmaceuticals, Inc.$20.6M2.50%2.50%Not reportedQ4 2024
RAPTRAPT Therapeutics, Inc.$19.4M2.36%2.07%Not reportedQ4 2023
CNTACentessa Pharmaceuticals PLC$18.8M2.28%0.50%-9.6%Q1 2023
PHVSPharvaris N.V.$18.6M2.26%1.03%-7.1%Q3 2024
LXEOLexeo Therapeutics, Inc.$17.1M2.08%2.36%NewQ4 2025
BBOTBridgeBio Oncology Therapeutics, Inc.$13.1M1.59%1.30%Not reportedQ1 2024
DBVTDBV Technologies S.A.$11M1.34%0.34%-43.6%Q2 2025
EVMNEvommune, Inc.$8.56M1.04%1.59%NewQ4 2025
DTILPrecision Biosciences Inc$7.98M0.97%7.96%NewQ4 2025
CRBPCorbus Pharmaceuticals Holdings, Inc.$7.77M0.94%5.42%-14.4%Q1 2024
UNCYUnicycive Therapeutics, Inc.$5.77M0.70%4.52%Not reportedQ3 2024
PEPGPepGen Inc.$4.56M0.55%1.02%Not reportedQ1 2024
Q3 2025Reported Nov 14, 202525 positions
ABVXAbivax S.A.$112M17.05%2.09%+4.6%Q1 2025
DNTHDianthus Therapeutics, Inc.$95.1M14.41%5.64%+3.2%Q3 2023
GOSSGossamer Bio, Inc.$44.8M6.80%7.37%-7.1%Q4 2020
COGTCogent Biosciences, Inc.$41.3M6.26%2.06%+4.0%Q3 2024
AVBPArriVent BioPharma, Inc.$36.4M5.51%4.82%+1.3%Q1 2024
OCULOcular Therapeutix, Inc$30.7M4.65%1.50%+8.2%Q1 2024
TSHATaysha Gene Therapies, Inc.$29.7M4.49%3.31%-28.0%Q4 2020
MRUSMerus N.V.$29M4.40%0.41%-20.8%Q1 2021
TRVITrevi Therapeutics, Inc.$25.8M3.90%2.20%-23.3%Q1 2025
MNMDDefinium Therapeutics, Inc.$25.1M3.81%Not reportedNot reportedQ1 2024
APLSApellis Pharmaceuticals, Inc.$20.4M3.10%0.71%Not reportedQ4 2020
KYMRKymera Therapeutics, Inc.$20.4M3.09%0.50%+35.3%Q2 2021
CNTACentessa Pharmaceuticals PLC$20.1M3.05%0.62%-19.4%Q1 2023
PHVSPharvaris N.V.$18M2.73%1.33%+7.4%Q3 2024
KALVKalVista Pharmaceuticals, Inc.$15.5M2.35%2.52%Not reportedQ4 2024
CRBPCorbus Pharmaceuticals Holdings, Inc.$14.1M2.14%8.90%Not reportedQ1 2024
BBOTBridgeBio Oncology Therapeutics, Inc.$12.1M1.83%1.32%+317.2%Q1 2024
DBVTDBV Technologies S.A.$10.2M1.54%0.74%Not reportedQ2 2025
NUVBNuvation Bio Inc.$10.1M1.54%0.81%-65.1%Q4 2023
CDTXCidara Therapeutics, Inc.$9.58M1.45%0.34%NewQ3 2025
MAZEMaze Therapeutics, Inc.$4.61M0.70%0.37%Not reportedQ1 2025
NGNENeurogene Inc.$4.37M0.66%1.71%-16.8%Q3 2024
UNCYUnicycive Therapeutics, Inc.$4.36M0.66%4.80%Not reportedQ3 2024
PEPGPepGen Inc.$3.23M0.49%2.13%Not reportedQ1 2024
GPCRStructure Therapeutics Inc.$3.22M0.49%0.06%Not reportedQ1 2023
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.